Connect Biopharma Highlights 2026 Priorities and New Mechanism Data for Rademikibart

Connect Biopharma highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026. Development Highlights: New mechanism of action data supports the use of rademikibart in combination with standard of care beta-agonists to reverse acute exacerbations and for maintenance therapy in asthma and COPD; Initiated Phase 1b clinical pharmacology study with IV rademikibart to evaluate opportunity to reverse bronchoconstriction even more quickly than subcutaneous dosing; expect to report topline results in the first quarter of 2026; Recruitment of participants into the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies evaluating the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations is ongoing with topline data from both studies expected in mid-2026.